| Proposed Ticker: | CGNS | One Kendall Square, Building 300 | |
| Exchange: | NASDAQ-National Market | Cambridge, Massachusetts 02139 | |
| Industry: | Service | (617) 374-9090 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 12/18/96 | |
| U.S. Shares Filed: | 2,500,000 | Filing Range: | $11.00 - $13.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $30,000,000 | |
| Primary Shares: | 2,500,000 | Expenses: | $750,000 | |
| Secondary Shares: | 0 | Shs Out After: | 10,103,815 | |
| Manager | Tier | Phone |
| Cowen & Company | Lead Manager | (212) 495-6000 |
| Montgomery Securities | Co-manager | (415) 627-2220 |
| Auditor: Arthur Andersen | |||||
| 9 Month Ending Financials | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 9/30/96 | 9/30/95 | 9/30/96 | ||
| Revenue: | $2.90 | $2.17 | $2.09 | Assets: | $12.76 |
| Net Income: | -$2.40 | -$10.44 | -$1.79 | Liabilities: | $5.17 |
| EPS: | -$0.31 | -$1.35 | Equity: | $7.59 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a drug discovery company that applies its two complementary technology platforms, Drug Discovery Genomics and Advanced Drug Selection Technologies, to key rate limiting steps in identifying new drugs. These rate limiting steps are the translation of genomic information not novel drug targets and the selection and identification from sources of chemical diversity of drug leads that interact with drug targets. The company's Drug Discovery Genomics platform includes proprietary gene technologies and expertise in microbial model systems used to determine the function of genes and to prioritize drug targets. The company's Advanced Drug Selection Technologies combine the steps of drug screening, chemical selection and structural analysis into an integrated process designed to identify drug leads faster than conventional methods. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for repayment of the $3 million promissory note to PerSeptive, research and development, expansion of its laboratory facilities, working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.